Literature DB >> 23323146

New agents on the horizon in hepatocellular carcinoma.

Andrew X Zhu1.   

Abstract

Despite the successful approval and extensive application of sorafenib, the prognosis for patients with advanced hepatocellular carcinoma (HCC) remains poor. Fortunately, there have been renewed and continued interests and active research in developing other molecularly targeted agents in HCC during the past few years. While there is early evidence of antitumor activity of several agents in phase I/II studies, phase III efforts with a few targeted agents have failed, highlighting the challenges of new drug development in HCC. This review summarizes the current status of other molecularly targeted agents under development in advanced HCC.

Entities:  

Keywords:  EGFR inhibitors; Met inhibitors; bevacizumab; brivanib; everolimus; hepatocellular carcinoma; linifanib; sorafenib; sunitinib; targeted agents

Year:  2013        PMID： 23323146      PMCID： PMC3539273          DOI： 10.1177/1758834012458480

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN： 1758-8340            Impact factor:   8.168


  38 in total

1.  Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma.

Authors:  Bert H O'Neil; Laura W Goff; John Sae Wook Kauh; Jonathan R Strosberg; Tanios S Bekaii-Saab; Ruey-Min Lee; Aslamuzzaman Kazi; Dominic T Moore; Maria Learoyd; Richard M Lush; Said M Sebti; Daniel M Sullivan
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

2.  Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma.

Authors:  K Harada; G Shiota; H Kawasaki
Journal:  Liver       Date:  1999-08

3.  Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).

Authors:  Dieter Koeberle; Michael Montemurro; Panagiotis Samaras; Pietro Majno; Mathew Simcock; Andreas Limacher; Stefanie Lerch; Katalin Kovàcs; Roman Inauen; Vivianne Hess; Piercarlo Saletti; Markus Borner; Arnaud Roth; György Bodoky
Journal:  Oncologist       Date:  2010-03-04

4.  Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.

Authors:  Abby B Siegel; Emil I Cohen; Allyson Ocean; Deborah Lehrer; Alec Goldenberg; Jennifer J Knox; Helen Chen; Sean Clark-Garvey; Alan Weinberg; John Mandeli; Paul Christos; Madhu Mazumdar; Elizabeta Popa; Robert S Brown; Shahin Rafii; Jonathan D Schwartz
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

5.  A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas.

Authors:  Tanios Bekaii-Saab; Joseph Markowitz; Nichole Prescott; Wolfgang Sadee; Nyla Heerema; Lai Wei; Zunyan Dai; Audrey Papp; Angela Campbell; Kristy Culler; Catherine Balint; Bert O'Neil; Ruey-Min Lee; Mark Zalupski; Janet Dancey; Helen Chen; Michael Grever; Charis Eng; Miguel Villalona-Calero
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 12.531

6.  Pivotal role of mTOR signaling in hepatocellular carcinoma.

Authors:  Augusto Villanueva; Derek Y Chiang; Pippa Newell; Judit Peix; Swan Thung; Clara Alsinet; Victoria Tovar; Sasan Roayaie; Beatriz Minguez; Manel Sole; Carlo Battiston; Stijn Van Laarhoven; Maria I Fiel; Analisa Di Feo; Yujin Hoshida; Steven Yea; Sara Toffanin; Alex Ramos; John A Martignetti; Vincenzo Mazzaferro; Jordi Bruix; Samuel Waxman; Myron Schwartz; Matthew Meyerson; Scott L Friedman; Josep M Llovet
Journal:  Gastroenterology       Date:  2008-08-20       Impact factor: 22.682

7.  Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.

Authors:  Andrew X Zhu; Keith Stuart; Lawrence S Blaszkowsky; Alona Muzikansky; Donald P Reitberg; Jeffrey W Clark; Peter C Enzinger; Pankaj Bhargava; Jeffrey A Meyerhardt; Kerry Horgan; Charles S Fuchs; David P Ryan
Journal:  Cancer       Date:  2007-08-01       Impact factor: 6.860

8.  Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.

Authors:  Melanie B Thomas; Romil Chadha; Katrina Glover; Xuemei Wang; Jeffrey Morris; Thomas Brown; Asif Rashid; Janet Dancey; James L Abbruzzese
Journal:  Cancer       Date:  2007-09-01       Impact factor: 6.860

9.  A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.

Authors:  Ramesh K Ramanathan; Chandra P Belani; Deepti A Singh; Michael Tanaka; Heinz-Josef Lenz; Yun Yen; Hedy L Kindler; Syma Iqbal; Jeff Longmate; Philip C Mack; Georg Lurje; Regina Gandour-Edwards; Janet Dancey; David R Gandara
Journal:  Cancer Chemother Pharmacol       Date:  2009-01-24       Impact factor: 3.333

10.  Elevation of transforming growth factor alpha and its relationship to the epidermal growth factor and alpha-fetoprotein levels in patients with hepatocellular carcinoma.

Authors:  Y C Yeh; J F Tsai; L Y Chuang; H W Yeh; J H Tsai; D L Florine; J P Tam
Journal:  Cancer Res       Date:  1987-02-01       Impact factor: 12.701
View more
  11 in total

Review 1.  Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.

Authors:  Yujie Zhao; Alex A Adjei
Journal:  Oncologist       Date:  2015-05-22

Review 2.  Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status.

Authors:  Lumin Chen; Jihong Sun; Xiaoming Yang
Journal:  Cancer Lett       Date:  2015-10-22       Impact factor: 8.679

3.  Hepatocellular Carcinoma: Current Questions and Future Directions.

Authors:  Robert G Gish
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-03

Review 4.  The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis.

Authors:  Carmen Berasain; Matías A Avila
Journal:  J Gastroenterol       Date:  2013-12-10       Impact factor: 7.527

Review 5.  Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience.

Authors:  Matthew M Yeh; Raymond S Yeung; Smith Apisarnthanarax; Renuka Bhattacharya; Carlos Cuevas; William P Harris; Tony Lim Kiat Hon; Siddharth A Padia; James O Park; Kevin M Riggle; Sayed S Daoud
Journal:  World J Hepatol       Date:  2015-06-18

Review 6.  Molecular therapies in hepatocellular carcinoma: what can we target?

Authors:  Roberto Galuppo; Dinesh Ramaiah; Oscar Moreno Ponte; Roberto Gedaly
Journal:  Dig Dis Sci       Date:  2014-02-27       Impact factor: 3.199

7.  Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study.

Authors:  Shukui Qin; Ying Cheng; Jun Liang; Lin Shen; Yuxian Bai; Jianfeng Li; Jia Fan; Lijian Liang; Yaqi Zhang; Gang Wu; Kun-Ming Rau; Tsai-Shen Yang; Zhixiang Jian; Houjie Liang; Yan Sun
Journal:  Oncologist       Date:  2014-09-15

8.  Telomerase activated thymidine analogue pro-drug is a new molecule targeting hepatocellular carcinoma.

Authors:  Mirko Tarocchi; Simone Polvani; Anna Julie Peired; Giada Marroncini; Massimo Calamante; Elisabetta Ceni; Daniela Rhodes; Tommaso Mello; Giuseppe Pieraccini; Alessandro Quattrone; Claudio Luchinat; Andrea Galli
Journal:  J Hepatol       Date:  2014-05-23       Impact factor: 25.083

Review 9.  Pediatric hepatocellular carcinoma: challenges and solutions.

Authors:  Irene Schmid; Dietrich von Schweinitz
Journal:  J Hepatocell Carcinoma       Date:  2017-01-16

10.  Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma.

Authors:  Masafumi Ikeda; Shinichi Ohkawa; Takuji Okusaka; Shuichi Mitsunaga; Satoshi Kobayashi; Chigusa Morizane; Ikue Suzuki; Shunsuke Yamamoto; Junji Furuse
Journal:  Cancer Sci       Date:  2014-03-25       Impact factor: 6.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.